Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(16):1102-1103; doi:10.1093/jnci/djj350
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Correction (v98,p1442)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McNeil, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNeil, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Two Targets, One Drug for New EGFR Inhibitors

Caroline McNeil

The first 150 words of the full text of this article appear below.

The new drug that garnered the most media attention at this year's American Society of Clinical Oncology meeting was lapatinib (Tykerb), a targeted agent that showed a tumor response in metastatic breast cancer resistant to trastuzumab (Herceptin). In an international phase III trial, lapatinib with capecitabine significantly improved the time to progression compared with capecitabine alone. The findings prompted early closing of the trial and put lapatinib on track for regulatory review later this year.

But lapatinib drew attention for another reason as well: It was designed to hit two receptors at once—the epidermal growth factor receptor (EGFR) and HER2. Both receptors are important targets of already-approved drugs: Trastuzumab targets HER2, and cetuximab, gefitinib, and erlotinib aim at EGFR. But as the first successful agent designed to hit both receptors, lapatinib marks the coming of age of a new generation.

"We're moving now from the era of single-targeted agents to . . . [Full Text of this Article]

Two Targets Versus One

Multitargeted Agent Versus Combined Therapy

Small Differences

Dual-Target EGFR Drugs in the Pipeline


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. Banerjee, M. Zvelebil, P. Furet, U. Mueller-Vieira, D. B. Evans, M. Dowsett, and L.-A. Martin
The Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 Inhibits Aromatase
Cancer Res., June 1, 2009; 69(11): 4716 - 4723.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Croyle, N. Akeno, J. A. Knauf, D. Fabbro, X. Chen, J. E. Baumgartner, H. A. Lane, and J. A. Fagin
RET/PTC-Induced Cell Growth Is Mediated in Part by Epidermal Growth Factor Receptor (EGFR) Activation: Evidence for Molecular and Functional Interactions between RET and EGFR
Cancer Res., June 1, 2008; 68(11): 4183 - 4191.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. R. Emlet, K. A. Brown, D. L. Kociban, A. A. Pollice, C. A. Smith, B. B. L. Ong, and S. E. Shackney
Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines
Mol. Cancer Ther., October 1, 2007; 6(10): 2664 - 2674.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Mimeault and S. K. Batra
Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies
Ann. Onc., October 1, 2007; 18(10): 1605 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. R. Patel and M. P. Mehta
Targeted Therapy for Brain Metastases: Improving the Therapeutic Ratio
Clin. Cancer Res., March 15, 2007; 13(6): 1675 - 1683.
[Abstract] [Full Text] [PDF]